The global deep brain stimulation market is growing at a CAGR of 11%, which puts it at a value of $9.4 billion in 2019 after recording $4.5 in 2012. Almost one million people in the United States and 10 million people around the world suffer from Parkinson’s disease.

About Parkinson’s Disease
Parkinson’s disease is the second most common neurodegenerative movement disorder, next to Alzheimer’s. With the currently increasing geriatric population, there will be an increase in the number of patients diagnosed with Parkinson’s disease. Increasing awareness about the disease along with other neurological movement related diseases have created space for growth in the deep brain stimulation devices market. About 12 percent of deaths worldwide are caused due to neurodegenerative diseases, of which 85 percent are cerebrovascular.

Browse Deep Brain Stimulation Devices Market Research Report with complete TOC at http://www.transparencymarketresearch.com/deep-brain-stimulator-market.html


Treatment Methods for Parkinson’s
The most effective treatment method for controlling initial stage Parkinson’s disease is drug therapy. The amount and potency of drugs required to control Parkinson’s disease at a late stage are substantial, which is why Deep Brain Stimulation (DBS) can prove to be a better option.

DBS is a surgical treatment used to control the involuntary symptoms of Parkinson’s disease. DBS is and FDA approved, clinically proven and effective treatment option for mild to severe Parkinson’s disease. The Deep Brain Stimulation device market is expected to expand at a positive rate between 2013 and 2019.

Get Free Sample Report at http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1435


DBS Market Drivers and Restraints
The increasing number of patients diagnosed with Parkinson’s disease is the prime growth driver for the DBS device market. As a larger percentage of the population approaches old age, the increasing risk and prevalence of Parkinson’s disease could prompt the top medical organizations and governments to help research for more effective techniques. DBS remains one of the more effective treatment methods currently. Other treatment options for Parkinson’s disease include:
Chemotherapy
Stem cell therapy
Surgical treatment
Physical therapy

Some of the common drug therapies include the use of:
Levodopa/Cabidopa
Anti-cholinergics
Dopamine agnostics
MAO-B inhibitors
Catechol-O-methyltransferase (COMT) inhibitors

Browse More Medical Devices Related Research Reports at http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html


One of the greatest disadvantages of drug therapy is that prolonged usage will weaken their effects. Once their effectiveness starts reducing, they become nothing more than a costly redundancy for most patients, who then start looking for other options. Surgical treatment becomes the leading option for later stages of Parkinson’s disease, which makes DBS a far safer surgical option than other open surgeries such as pallidotomy, thalamotomy and subthalamotomy.

The key restraint for the DBS market is the involvement of high costs in the surgical equipment and procedure which discourages many patients to resort to drug therapy instead. Many original equipment manufacturers have responded to the increasing burden of Parkinson’s disease on healthcare facilities and governments, and have developed advanced research labs to study better methods of treating Parkinson’s disease.

Browse Blog http://tmrresearch.wordpress.com/


Advancements in the DBS Market
A research team from Tel Aviv University has worked on a biometric advanced chip implant which they call the Rehabilitation Nano Chip (ReNaChip). It could provide crucial aid to healthcare professionals and neurosurgeons to recover brain functions. The ReNaChip can also provide a more effective DBS treatment method by providing electrical stimulation to specific parts of the brain with a higher accuracy. Boston Scientific is at work on their flagship product called “Vercise DBS”. It works by enhancing the battery life of a regular DBS device by 25 years, providing invaluable aid in terms of effectiveness and cost-efficiency. The leading organizations in DBS research and application are St. Jude Medical and Medtronic. They have constantly placed investments in the research and development of DBS devices.